In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
AveXis nets $432mm in FOPO to fund neuromuscular disease programs
01 Mar 2018
AveXis Inc. (gene therapies for rare musculoskeletal and neurological genetic diseases) netted $432mm in a public offering of 4.5mm shares (including the overallotment) at $102. Concurrent with the financing, the company announced an expanded development program for lead compound AVXS101 in spinal muscular atrophy (SMA) Type 1 (for which it has orphan drug, breakthrough therapy, and fast track designations), including testing the Phase I compound in new SMA patient populations such as Type 2 and Type 3 (grouped based on disease onset and severity). AveXis will use the proceeds to fund research, manufacturing, development, licensing, and pre-commercialization activities for AVXS101 in SMA as well as clinical activities for other programs in Rett syndrome and ALS.
Gene Therapy, Cell Therapy
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?